Apellis Pharmaceuticals, Inc. (APLS) Financials

APLS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 788.7 million 594.2 million
2023-09-30 818.2 million 585.9 million
2023-06-30 915.6 million 570.2 million
2023-03-31 978.9 million 566.7 million

APLS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -98.0 million 26.2 million
2023-09-30 -169.1 million 21.6 million
2023-06-30 -150.5 million 29.3 million
2023-03-31 -177.9 million 28.8 million

APLS Net Income

No data available :(

APLS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 352.3 million - 17.9 million
2023-09-30 452.4 million - 16.6 million
2023-06-30 616.3 million - 17.9 million
2023-03-31 765.1 million - 19.1 million

APLS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 121.2 million
2023-09-30 120.3 million
2023-06-30 119.3 million
2023-03-31 113.9 million

APLS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 95000 69.3 million 141.7 million -
2023-09-30 47000 79.4 million 145.6 million -
2023-06-30 372000 95.7 million 111.4 million -
2023-03-31 259000 110.0 million 102.1 million -

APLS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 146.4 million 19.9 million
2023-09-30 99.2 million 22.4 million
2023-06-30 95.0 million 8.4 million
2023-03-31 44.8 million 7.8 million

APLS

Price: $47.28

52 week price:
19.83
94.75

Earnings Per Share: -4.45 USD

P/E Ratio: -12.87

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 1.2 million

Ebitda: -11.6 million

Market Capitalization: 6.9 billion

Links: